<DOC>
	<DOCNO>NCT00631072</DOCNO>
	<brief_summary>The purpose research study determine whether purify grow population cell participant blood ( iNKT cell ) safely give back participant increase number , whether cell stimulate body immune response cancer . These iNKT cell use laboratory study information research study suggest increase number cell blood stimulate immune response tumor .</brief_summary>
	<brief_title>In Vitro Expanded Autologous Invariant Natural Killer Cells Cancer</brief_title>
	<detailed_description>- The first step study collect iNKT cell participant peripheral blood . For procedure intravenous catheter use remove blood . The white blood cell remove blood red blood cell plasma return participant ( leukopheresis ) . - We purify iNKT cell collect white blood cell , grow culture plat lab strictly control sterile condition . This take 4-6 week . - If successful grow iNKT cell large enough number , divide 3 equal dos . Participants receive one dose cell intravenous infusion every 2 week day 1 , 15 29 . A blood sample take immediately infusion , 1 4 hour infusion . Participants ask return blood sample day 2 , 3 , 4 8 infusion . - The initial group 3-6 participant receive therapy iNKT cell infusion . However , subsequent group 6 patient addition receive GM-CSF , stimulate immune system may increase effect iNKT cell . This medication administer subcutaneous injection give daily 10 day begin day second third infusion . - Participants research study 14 week , include time cell purification culture , treatment , follow-up observation .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Stage IV melanoma ECOG Performance Status 01 Estimated life expectancy 6 month great 18 year age old Adequate renal , hepatic hematological function outline protocol Adequate pulmonary cardiac function outline protocol Prior therapy must discontinue least 4 week prior leukopheresis obtain iNKT cell . This include palliative surgery radiation therapy , may use prior leukopheresis interval leukopheresis iNKT cell reinfusion Melanoma patient must brain metastasis base negative MRI obtain within 4 week prior screen , must history brain metastases No significant medical , surgical psychiatric condition , judgment PI , would interfere compliance protocol regimen Pregnant nursing woman Active systemic infection , positive HIV , HBV , HCV serology , immune deficiency disease Autoimmune disease currently require systemic therapy immunosuppressive agent Known hypersensitivity GMCSF DMSO Other active malignancy squamous cell basal cell skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>iNKT</keyword>
	<keyword>vitro autologous iNKT</keyword>
</DOC>